ArticleJournal of translational medicine2004
Melanoma-restricted genes.
Article in Journal of translational medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?Clinical & experimental metastasis · 2010Pooled it
- Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.Genome biology · 2007Trial
- IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes.British journal of cancer · 2013Article
- The stable traits of melanoma genetics: an alternate approach to target discovery.BMC genomics · 2012Article
- An immunologic portrait of cancer.Journal of translational medicine · 2011Review
- Cooperativity of adaptive and innate immunity: implications for cancer therapy.Cancer immunology, immunotherapy : CII · 2011Review
- Analysis of vaccine-induced T cells in humans with cancer.Advances in experimental medicine and biology · 2010Article
- Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.Journal of translational medicine · 2009Article
- A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".Journal of translational medicine · 2008Article
- Article
- A gene expression signature associated with survival in metastatic melanoma.Journal of translational medicine · 2006Article
- Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients.Journal of translational medicine · 2006Article
- Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy.Journal of translational medicine · 2006Article
- Gene expression profiling of melanoma cells - searching the haystack.Journal of translational medicine · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
Human metastatic cutaneous melanoma has gained a well deserved reputation for its immune responsiveness. The reason(s) remain(s) unknown. We attempted previously to characterize several variables that may affect the relationship between tumor and host immune cells but, taken one at the time, none yielded a convincing explanation. With explorative purposes, high-throughput technology was applied here to portray transcriptional characteristics unique to metastatic cutaneous melanoma that may or may not be relevant to its immunogenic potential. Several functional signatures could be identified descriptive of immune or other biological functions. In addition, the transcriptional profile of metastatic melanoma was compared with that of primary renal cell cancers (RCC) identifying several genes co-coordinately expressed by the two tumor types. Since RCC is another immune responsive tumor, commonalities between RCC and melanoma may help untangle the enigma of their potential immune responsiveness. This purely descriptive study provides, therefore, a map for the investigation of metastatic melanoma in future clinical trials and at the same time may invite consideration of novel therapeutic targets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.